BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdelhamid AM, Elsheakh AR, Abdelaziz RR, Suddek GM. Empagliflozin ameliorates ethanol-induced liver injury by modulating NF-κB/Nrf-2/PPAR-γ interplay in mice. Life Sciences 2020;256:117908. [DOI: 10.1016/j.lfs.2020.117908] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 El-kashef DH, Sewilam HM. Empagliflozin mitigates methotrexate-induced hepatotoxicity: Targeting ASK-1/JNK/Caspase-3 pathway. International Immunopharmacology 2023;114:109494. [DOI: 10.1016/j.intimp.2022.109494] [Reference Citation Analysis]
2 Nakhal MM, Aburuz S, Sadek B, Akour A. Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder. Molecules 2022;27:7174. [DOI: 10.3390/molecules27217174] [Reference Citation Analysis]
3 Liao Y, Luo F, Tang S, Huang J, Yang Y, Wang S, Jiang T, Man Q, Liu S, Wu Y. Network analysis and experimental pharmacology study explore the protective effects of Isoliquiritigenin on 5-fluorouracil-Induced intestinal mucositis. Front Pharmacol 2022;13:1014160. [DOI: 10.3389/fphar.2022.1014160] [Reference Citation Analysis]
4 Heimke M, Lenz F, Rickert U, Lucius R, Cossais F. Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia. Cells 2022;11:3107. [PMID: 36231069 DOI: 10.3390/cells11193107] [Reference Citation Analysis]
5 Huang Y, Jiang J, Wang W, Guo J, Yang N, Zhang J, Liu Q, Chen Y, Hu T, Rao C. Zanthoxylum armatum DC. extract induces liver injury via autophagy suppression and oxidative damage by activation of mTOR/ULK1 pathway. Toxicon 2022;217:162-72. [PMID: 35977614 DOI: 10.1016/j.toxicon.2022.08.008] [Reference Citation Analysis]
6 Amer RM, Eltokhy AK, Elesawy RO, Barakat AN, Basha E, Eldeeb OS, Aboalsoud A, Elgharabawy NM, Ismail R. The Ameliorative Effect of Empagliflozin in Vigabatrin-Induced Cerebellar/Neurobehavioral Deficits: Targeting mTOR/AMPK/SIRT-1 Signaling Pathways. Molecules 2022;27:3659. [PMID: 35744783 DOI: 10.3390/molecules27123659] [Reference Citation Analysis]
7 Li Q, Cao Q, Yuan Z, Wang M, Chen P, Wu X. A novel self-nanomicellizing system of empagliflozin for oral treatment of acute pancreatitis: An experimental study. Nanomedicine: Nanotechnology, Biology and Medicine 2022;42:102534. [DOI: 10.1016/j.nano.2022.102534] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Li J, Lu J, Lv S, Sun S, Liu C, Xu F, Sun H, Yang J, Wang X, Zhong X, Lu J. Linoleic acid pathway disturbance contributing to potential cancerization of intrahepatic bile duct stones into intrahepatic cholangiocarcinoma. BMC Gastroenterol 2022;22:269. [PMID: 35637430 DOI: 10.1186/s12876-022-02354-2] [Reference Citation Analysis]
9 Dong D, Zhang Y, He H, Zhu Y, Ou H. Alpinetin inhibits macrophage infiltration and atherosclerosis by improving the thiol redox state: Requirement of GSk3β/Fyn-dependent Nrf2 activation. FASEB J 2022;36:e22261. [PMID: 35332570 DOI: 10.1096/fj.202101567R] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ahmed S, El-sayed MM, Kandeil MA, Khalaf MM. Empagliflozin attenuates Neurodegeneration through Antioxidant, Anti-inflammatory, and Modulation of α-synuclein and Parkin Levels in Rotenone-Induced Parkinson’s Disease in Rats. Saudi Pharmaceutical Journal 2022. [DOI: 10.1016/j.jsps.2022.03.005] [Reference Citation Analysis]
11 Zaghloul MS, Elshal M, Abdelmageed ME. Preventive empagliflozin activity on acute acetic acid-induced ulcerative colitis in rats via modulation of SIRT-1/PI3K/AKT pathway and improving colon barrier. Environ Toxicol Pharmacol 2022;:103833. [PMID: 35218923 DOI: 10.1016/j.etap.2022.103833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Abd El-Fattah EE, Saber S, Youssef ME, Eissa H, El-Ahwany E, Amin NA, Alqarni M, Batiha GE, Obaidullah AJ, Kaddah MMY, Ahmed Gaafar AG, Mourad AAE, Mostafa-Hedeab G, Abdelhamid AM. AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma. Front Pharmacol 2021;12:720173. [PMID: 35095479 DOI: 10.3389/fphar.2021.720173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Li JJ, Lu XY, Jia P, Zhu L, Wang A, Bu FT, Zhang YL, Huang C, Li J. O-alkyl and o-benzyl hesperetin derivative-1L attenuates inflammation and protects against alcoholic liver injury via inhibition of BRD2-NF-κB signaling pathway. Toxicology 2022;466:153087. [PMID: 34974135 DOI: 10.1016/j.tox.2021.153087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Abdelhamid AM, Youssef ME, Abd El-Fattah EE, Gobba NA, Gaafar AGA, Girgis S, Shata A, Hafez AM, El-Ahwany E, Amin NA, Shahien MA, Abd-Eldayem MA, Abou-Elrous M, Saber S. Blunting p38 MAPKα and ERK1/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-κB inactivation in mice intoxicated with carbon tetrachloride. Life Sci 2021;286:120070. [PMID: 34688695 DOI: 10.1016/j.lfs.2021.120070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
15 Hüttl M, Markova I, Miklankova D, Zapletalova I, Poruba M, Haluzik M, Vaněčkova I, Malinska H. In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia. Int J Mol Sci 2021;22:11513. [PMID: 34768942 DOI: 10.3390/ijms222111513] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
16 Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stompór T. Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists. Int J Mol Sci 2021;22:10822. [PMID: 34639160 DOI: 10.3390/ijms221910822] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
17 Qiu L, Liu X, Li W, Liu Z, Xu C, Xia H. Downregulation of p300/CBP-associated factor inhibits cardiomyocyte apoptosis via suppression of NF-κB pathway in ischaemia/reperfusion injury rats. J Cell Mol Med 2021;25:10224-35. [PMID: 34601814 DOI: 10.1111/jcmm.16959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Abdelhamid AM, Elsheakh AR, Suddek GM, Abdelaziz RR. Telmisartan alleviates alcohol-induced liver injury by activation of PPAR-γ/ Nrf-2 crosstalk in mice. Int Immunopharmacol 2021;99:107963. [PMID: 34273638 DOI: 10.1016/j.intimp.2021.107963] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]